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Medical and Surgical Treatment
of Acute Right Ventricular Failure
Tim Lahm, MD,‡§ Charles A. McCaslin, MD,‡ Thomas C. Wozniak, MD,*
Waqas Ghumman, MD,‡ Yazid Y. Fadl, MD, MPH,¶ Omar S. Obeidat, MD,¶
Katie Schwab, PA,* Daniel R. Meldrum, MD*†#**
Indianapolis, Indiana
Acute right ventricular (RV) failure is a frequent and serious clinical challenge in the intensive care unit. It is usu-
ally seen as a consequence of left ventricular failure, pulmonary embolism, pulmonary hypertension, sepsis,
acute lung injury or after cardiothoracic surgery. The presence of acute RV failure not only carries substantial
morbidity and mortality, but also complicates the use of commonly used treatment strategies in critically ill pa-
tients. In contrast to the left ventricle, the RV remains relatively understudied, and investigations of the treat-
ment of isolated RV failure are rare and usually limited to nonrandomized observations. We searched PubMed
for papers in the English language by using the search words right ventricle, right ventricular failure, pulmonary
hypertension, sepsis, shock, acute lung injury, cardiothoracic surgery, mechanical ventilation, vasopressors, ino-
tropes, and pulmonary vasodilators. These were used in various combinations. We read the abstracts of the rele-
vant titles to confirm their relevance, and the full papers were then extracted. References from extracted papers
were checked for any additional relevant papers. This review summarizes the general measures, ventilation
strategies, vasoactive substances, and surgical as well as mechanical approaches that are currently used or ac-
tively investigated in the treatment of the acutely failing RV. (J Am Coll Cardiol 2010;56:1435–46) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.046r
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Right ventricular failure (RVF) in the intensive care unit
ICU) remains a formidable clinical challenge. Significant
omorbidities and hemodynamic instability are often
resent, and common therapeutic interventions may have
eleterious hemodynamic effects. The importance of the
ight ventricle (RV) is reflected in a recent publication from
National Heart, Lung, and Blood Institute working group,
hich suggested that studying the RV should be a priority
n cardiovascular research (1). Pathogenesis, physiology,
ymptoms, and diagnosis of RVF have recently been re-
iewed in detail (2–5) and are beyond the scope of this
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ccepted May 17, 2010.eview. We briefly review the causes, pathophysiology,
nd diagnosis of acute RVF in the ICU and focus on the
eneral measures, vasoactive substances, and surgical and
echanical approaches used in the treatment of the
cutely failing RV.
tiology and Pathophysiology of Acute RVF
VF results from any structural or functional process
ecreasing the ability of the RV to pump blood into the
ulmonary circulation. Causes include alterations in pre-
oad and diastolic filling, decreases in inotropy, and in-
reases in afterload (3) (Table 1). RV pre-load and diastolic
lling affect myocardial fiber length and contractility via the
rank-Starling mechanism, and both increases as well as
ecreases in pre-load may negatively affect RV function (3).
he most common etiologies of RVF in the ICU are left
entricular (LV) failure, RV ischemia, acute pulmonary
mbolism, pulmonary hypertension (PH), sepsis, acute lung
njury, cardiac tamponade, and post-cardiothoracic surgery
tates. Arrhythmias and pericardial, congenital, and/or val-
ular heart disease may also contribute (3). Acute RVF is
lso observed during acute chest syndrome in patients with
ickle cell disease (6). In the majority of these conditions,
V dysfunction prognosticates worse outcomes (5–8). The
athophysiology of acute RVF in critically ill patients is
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and/or arrhythmias, endotoxin-
and cytokine-induced decreases in
systolic and diastolic LV and RV
function, as well as afterload in-
creases from endothelial dysfunc-
tion, hypoxic pulmonary vasocon-
striction (HPV), and pulmonary
microthrombi and/or thromboem-
boli (1,5,8–11). LV dysfunction,
either cytokine-induced or due to
ischemia or nonischemic cardio-
myopathies, induces RV dysfunc-
tion via afterload increase, and/or
displacement of the interventricu-
lar septum toward the RV with
subsequent impairment of RV fill-
ing (known as ventricular inter-
dependence). Hypovolemia and
inflammation-induced capillary
leak alter RV function by decreas-
ing pre-load (8,9,11). Important
interactions between inflamma-
tion, sepsis, pulmonary endothelial
dysfunction with associated PH,
and RV and LV dysfunction have
recently been reviewed (8). Pro-
inflammatory cytokines like tu-
mor necrosis factor- directly sup-
press myocardial contractility (10).
Heightened oxygen demands from
increased heart rate, afterload, and
wall tension, combined with de-
reased coronary perfusion from hypotension, result in suben-
ocardial (1,2) and myocardial RV ischemia (8). Mechanical
entilation, certain drugs, and volume overload may further
lter RV function (3,4,12,13). These pathogenetic entities
Fig. 1) provide the rationale for the treatment strategies
utlined in this review.
iagnosis of RVF in the ICU
lthough no specific biomarker for RVF exists, serum chem-
stries aid in prognostication (Table 2) (14–20). Electrocardi-
graphy, although specific, lacks sensitivity (2,3,12). Once
hest X-ray or CT demonstrates signs of RV dysfunction,
VF is usually advanced and associated with high mortality
Fig. 2).
Pulmonary artery catheters (PACs) and transthoracic or
ransesophageal echocardiography remain the most reliable
ethods to diagnose RVF and evaluate the treatment
esponse in the ICU. Although PACs do not affect out-
omes in acute lung injury (21), they provide crucial
emodynamic information in acute RVF, particularly when
sed in combination with echocardiographic parameters of
Abbreviations
and Acronyms
BAS  balloon
atrioseptostomy
CO  cardiac output
HPV  hypoxic pulmonary
vasoconstriction
ICU  intensive care unit
iNO  inhaled nitric oxide
LV  left ventricular
LVAD  left ventricular
assist device
PA  pulmonary artery
PAC  pulmonary artery
catheter
PAH  pulmonary arterial
hypertension
PAP  pulmonary artery
pressure
PDE  phosphodiesterase
PH  pulmonary
hypertension
PVR  pulmonary vascular
resistance
RAP  right atrial pressure
RV  right ventricle
RVEF  right ventricular
ejection fraction
RVF  right ventricular
failure
VT  tidal volumeV function and indexes of tissue oxygenation. In addition ho directly measuring pulmonary artery pressure (PAP) and
ulmonary capillary wedge pressure, PACs allow measure-
ent and/or calculation of additional parameters like right
trial pressure (RAP), cardiac output (CO), mixed venous
xygen saturation, pulmonary vascular resistance (PVR),
nd RV stroke work index (Table 2) (22–27). PACs also
llow evaluation of the response to pharmacologic therapies
nd drug titration to specific end points. Importantly, a
ecrease in PAP may reflect decreasing right ventricular
jection fraction (RVEF) and worsening RVF (28). Al-
hough a chronically hypertrophied RV usually tolerates a
ignificantly elevated PAP, a RV without pre-existing hy-
ertrophy will not be able to generate a systolic PAP50 to
0 mm Hg.
The critical role of bedside echocardiography, especially
hen combined with specific markers of RV dysfunction,
uch as tricuspid annular plane systolic excursion index (29),
issue Doppler (30), and Tei index (31), cannot be overem-
hasized (Table 2) (3,32).
Whether newer predictors of fluid responsiveness (e.g.,
ariations in pulse pressure, systolic blood pressure, or stroke
olume) (33) can be of merit in isolated RVF needs further
tudy. In studies of various forms of shock, these are promising
ew techniques for patients in sinus rhythm and on mechanical
entilation (33). Mechanical insufflation increases intrathoracic
ressures, decreases RV pre-load, and increases RV afterload,
esulting in diminished RV and LV stroke volumes. These
hanges are more pronounced in patients whose RV operates
n the steep portion of the Starling curve, making dynamic
hanges in arterial waveform a sensitive indicator of RV
re-load dependence (33,34). Passive leg raising may better
redict fluid responsiveness in patients with arrhythmias and
pontaneous respirations (34). Cardiac magnetic resonance
maging is the most sensitive method to assess RV function
1–3,12); however, due to logistical issues, it is rarely used for
ritically ill patients.
reatment of Acute RVF
reatment strategies for acute RVF in the ICU are derived
rom the pathogenetic entities outlined previously. Major
omponents include volume optimization, RV inotropy
nhancement, and RV afterload reduction, the latter being
chieved through multiple interventions (Fig. 3). These
oals are achieved through careful volume management,
asopressor and/or inotrope therapy, selective pulmonary
asodilators, surgical and/or mechanical interventions, and,
f possible, specific measures directed against the underlying
tiology (Fig. 4).
eneral supportive ICU care. Infection prevention mea-
ures, thromboembolism and peptic ulcer prophylaxis, early
utritional support, glucose control, and (in stable mechan-
cally ventilated patients) daily interruptions of sedation
ombined with spontaneous breathing trials should be
pplied to all patients with acute RVF. The optimal
emoglobin level for patients with acute RVF remains to be
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October 26, 2010:1435–46 Treatment of Acute Right Heart Failureetermined. Although ICU patients usually benefit from a
onservative transfusion strategy (35), patients with shock or
eart failure may require higher hemoglobin levels (36,37).
his might be the case for patients with acute RVF as well.
learly, significant anemia in the setting of decreased tissue
xygenation should be corrected. Sodium restriction (in
olume overload states) and daily monitoring of body
eight and volume status are indicated.
reatments that attenuate HPV, optimize volume status,
nd target arrhythmias. Adequate oxygenation is of ut-
ost importance to avoid afterload increases due to HPV.
e therefore aim for oxygen saturations of 92%. As RV
unction is highly volume dependent, a careful balance
etween optimized pre-load and decreased afterload is
ssential. If pre-load is too low, RVEF will not be adequate.
owever, too much pre-load will cause the intraventricular
eptum to shift leftward, decrease LV output, and cause
ypotension through ventricular interdependence, especially
n the setting of high intrathoracic pressures or pericardial
isease (2,8). Therefore, careful administration of fluid
oluses, used in conjunction with noninvasive or invasive
ssessment of CO, is recommended. Vigorous fluid admin-
stration may be detrimental and should be discouraged (2).
iuretics are indicated for volume overload. Due to its
otential for greater weight and fluid loss than intravenous
iuretics, venovenous ultrafiltration is increasingly used for
auses of Acute RV Failure in the Intensive Care UnitTable 1 Causes of Acute RV Failure in the Intensive Care Unit
Left ventricular dysfunction Most common cau
RV co-involvement
ventricular inter
RV ischemia (via negative effects on inotropy and/or
relaxation or via arrhythmias)
RV infarction
Relative RV ischem
Afterload increase (endothelial dysfunction,
vasoconstriction, and/or mechanical obstruction)
Pulmonary arterial
Hypoxic pulmonary
Post-cardiothoracic
Pulmonary embolu
Pulmonary microth
Pulmonary stenosi
Acute chest syndro
Mechanical ventila
Pre-load decrease (via effects on RV fiber length
and contractility)
Hypovolemia/capil
Superior vena cava
Tricuspid stenosis
Cardiac tamponad
Mechanical ventila
Intrinsic myocardial disease Cardiomyopathies
Arrhythmogenic RV
Sepsis (cytokine-in
Congenital and valvular heart disease Ebstein’s anomaly
Tetralogy of Fallot
Transposition of th
Atrial septum defe
Anomalous pulmon
Tricuspid regurgita
Pulmonary regurgi
Mitral valve diseas
Pericardial disease (via negative effects on diastolic filling) Constrictive perica
Arrhythmias
ABG  coronary artery bypass grafting; CHD  congenital heart disease; PH  pulmonary hyperecompensated left heart failure (38). Whether this repre- (ents a feasible option in diuretic-resistant right heart failure
eeds further study. As the RV is extremely susceptible to
lterations in cardiac rhythm and ventricular synchrony
39), restoration of sinus rhythm and/or atrioventricular
ynchrony makes sense, but few studies have focused on this
atter in acute RVF specifically (2,3). Clearly, hemody-
amically significant bradycardias or tachyarrhythmias
hould be corrected. Digoxin marginally improves CO in
atients with severe PH in the short term (40). However,
ue to potential side effects and a narrow therapeutic
indow, routine use is discouraged (2,12). Beta-blocking
gents and angiotensin-converting enzyme inhibitors im-
rove RV hemodynamics in patients with biventricular
ailure and have theoretical benefits in isolated RVF (41,42),
ut their role in the latter is poorly studied.
trategies that avoid negative effects of mechanical
entilation on RV pre-load and afterload. Due to poten-
ial adverse hemodynamic effects, mechanical ventilation
eeds to be administered with caution and expertise. Higher
idal volume (VT) and positive end-expiratory pressure may
ncrease PAP and RAP, worsen tricuspid regurgitation, and
ncrease RV afterload (13). In addition, positive end-
xpiratory pressure may decrease pre-load by diminishing
enous return. Therefore, the lowest VT, plateau pressure,
nd positive end-expiratory pressure needed to provide
dequate ventilation and oxygenation should be used
ight heart failure
ctural or ischemic heart disease or indirect RV dysfunction due to
ence, pulmonary venous congestion, and/or arrhythmias
ondary to RV pressure or volume overload
ension and secondary forms of PH
onstriction
ry (CABG, corrective surgery for CHD, heart/lung transplantation, pneumonectomy)
(sepsis and acute lung injury)
utflow tract obstruction
sickle cell disease
k
ome
ition of diastolic filling)
asia
myocardial depression)
t arteries
nous return
; RV  right ventricular.se of r
in stru
depend
ia sec
hypert
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s
rombi
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Treatment of Acute Right Heart Failure October 26, 2010:1435–46ndothelial dysfunction (43). However, because permissive
ypercapnia can increase PAP and worsen RVF through
asoconstriction, excessive hypercapnia should be avoided
12,45). Hyperventilation, on the other hand, attenuates
cidosis-induced vasoconstriction and decreases PAP (46).
yperventilation can be used to lower PAP acutely, but
hould not be performed at the expense of a high VT.
ecause increases in respiratory rate can cause dynamic
yperinflation and increased intrathoracic pressures, airway
ressures and flow-time loops should be watched closely.
rone ventilation, although not affecting mortality in acute
ung injury, may unload the RV through effects on airway
ressure and improved alveolar ventilation (47). The effects
f high-frequency oscillatory ventilation on RV function are
oorly defined, although decreases in CO are described
48,49). Although transient improvements in oxygenation
ay also be achieved with recruitment maneuvers, these
ay cause decreased venous return and hypotension (50)
nd should therefore only be used with extreme caution
Figure 1 Mechanisms of RV Dysfunction in Critically Ill Patient
Right ventricular (RV) dysfunction occurs directly due to cardiodepressant effects o
indirectly due to left ventricular (LV) dysfunction, afterload increases from endothe
nary microthrombi, as well as pre-load decreases (induced or aggravated by capilla
affecting pre-load and/or afterload. Endotoxin and proinflammatory cytokines nega
nitric oxide; O2  oxygen; PGI2  prostacyclin; TNF  tumor necrosis factor.hen significant hypoxemia is present. atrategies that improve RVEF, increase RV perfusion
ressure, and minimize tachyarrhythmias and afterload.
notropes improve cardiac contractility and CO by in-
reasing cyclic adenosine monophosphate. Vasopressors
ncrease RV perfusion pressure, thereby attenuating sub-
ndocardial ischemia. All inotropes concomitantly target
he left ventricle (a desired effect in LV failure–induced
VF).
Dobutamine, the inotrope traditionally used in cardiac
ump failure, works through 1-receptor–mediated in-
reases in myocardial contractility. Concomitant 2 stimu-
ation induces vasodilation and decreases afterload. In acute
H, low-dose dobutamine (2 to 5 g/kg/min) increases CO
nd decreases PVR, whereas higher doses (5 to 10
g/kg/min) only induce tachycardia and increase myocar-
ial oxygen consumption without further improvements in
AP (12,51,52). In an animal model of acute RVF, dobut-
mine was superior to norepinephrine in improving RV
unction, likely due to superior inotropic properties and the
flammatory cytokines, cardiac microthrombi, and ischemia and/or arrhythmias or
function, hypoxic pulmonary vasoconstriction, pulmonary emboli, and/or pulmo-
k syndrome). Mechanical ventilation contributes to RV dysfunction by negatively
ffect RV function on several levels. ET  endothelin; IL  interleukin; NO s
f proin
lial dys
ry lea
tively absence of peripheral vasoconstriction (52). In acute and
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October 26, 2010:1435–46 Treatment of Acute Right Heart Failurehronic PH, the combination of dobutamine and inhaled
itric oxide (iNO) improved CO, decreased PVR, and
ncreased the PaO2/FiO2 ratio (51,53). However, dobut-
mine may cause hypotension through peripheral 2 stim-
lation, sometimes requiring the addition of a peripheral
asoconstrictor (e.g., norepinephrine) (12).
Milrinone, a selective phosphodiesterase (PDE)-3 inhib-
tor, also exerts inotropic and vasodilatory properties. Al-
hough decreasing PVR and increasing RVEF in acute and
hronic PH, use is limited by systemic vasodilation and
ypotension (54). Like dobutamine, milrinone can be com-
ined with iNO to augment pulmonary vasodilation while
inimizing hypotension and tachyarrhythmias (55). In-
aled milrinone minimizes hypotension but maintains ben-
ficial effects on PVR and RVEF (56) and even attenuates
ulmonary endothelial dysfunction (57). However, due to
elatively selective PDE-5 expression in the lung and
ypertrophied RV, PDE-5 inhibitors may be more effective
nd more pulmonary artery (PA) and RV specific than
DE-3 inhibitors (58,59).
Norepinephrine increases inotropy through 1 agonism.
oncomitant stimulation of 1-receptors increases RV per-
verview of Serum Markers, Hemodynamic Parameters, andchocardi graphic Variables Used in the Diagnosis of Acute RV FaTable 2 Overview of S rum Markers, Hemodynamic ParametersEchocardiographic Variables Used in the Diagnosis of A
BNP, NT-proBNP, troponin Increase in LV dysfunct
BNP predicts survival in
increased mortality (
BNP 168 pg/ml ident
Risk stratification in pa
Sodium 136 mmol/l predicts
Predicts survival in PAH
Creatinine Predicts survival in PAH
increased mortality (
C-reactive protein Predicts survival in PAH
increased mortality (
Transaminases Increase reflects hepati
Prognostic value not es
Growth differentiation factor-15 Stress responsive, trans
Independent predictor of
Risk stratification in PA
Right atrial pressure, cardiac index Strongest hemodynami
Right atrial pressure 1
PVR Differentiates whether
PVR 1,000–1,200 dyn
septostomy in severe
Right ventricular stroke work index Prognosticates RVF afte
Easily obtained via PAC
Pulmonary artery impedance Evaluates and integrate
Superior and more com
RVEF, RA and RV volume, tricuspid regurgitation,
ventricular septal shift, pericardial effusion
Established and readily
Limited by marked pre-
Right ventricular systolic pressure Calculated from tricusp
Off by 10 mm Hg in a
TAPSE, tissue Doppler, Tei index More specific and less p
Established prognostic
or a more detailed description of assessment of RV function, please see Haddad et al. (3).
easurements, can be determined by cardiac magnetic resonance imaging.
BNP  B-type natriuretic peptide; CTEPH  chronic thromboembolic pulmonary hypertension; L
eptide; PAC pulmonary artery catheter; PAH pulmonary arterial hypertension; PAP pulmona
esistance; RA  right atrial; RV  right ventricular; RVF  right ventricular failure; RVEF  rightusion pressure and CO, as seen in a model of acute pulmonary embolism–induced RVF (60). Concerns about
ncreases in PVR and PAP exist, but were not observed in
hat particular study. Norepinephrine may therefore be
eneficial in hypotensive and tachycardic patients not tol-
rating dobutamine, but the latter remains the preferred
notrope for PH and/or acute RVF without significant
ypotension (12,52).
Levosimendan sensitizes cardiac troponin C to the effects
f intracellular calcium, thereby increasing contractility
ithout increasing oxygen consumption. Levosimendan
lso has global vasodilatory and anti-ischemic properties
hat are mediated by activation of adenosine triphosphate-
ensitive potassium channels in mitochondria of vascular
mooth muscle cells (61) and by endothelin-1 inhibition
62). The drug increases CO, decreases PVR, and improves
egional perfusion, together with a protective effect against
ndothelial dysfunction by inhibiting expression of soluble
dhesion molecules (63). Levosimendan attenuates injury-
nduced RV and LV dysfunction and increases regional
lood flow and global oxygen transport (64). Although
haring the vasodilatory effects of dobutamine and milri-
one, it seems to have more specific pulmonary vasodilatory
in the Intensive Care Unit
RV Failure in the Intensive Care Unit
al failure, sepsis, but significant RV dysfunction less likely if values normal
RVF in PAH; increased levels (1,415 pg/ml vs. 628 pg/ml) associated with
V dysfunction in CTEPH patients with 88% sensitivity, 86% specificity (15)
with subtle RV dysfunction during acute, nonmassive PE (16,17)
d increased risk of death in PAH patients (18)
nts with acute RVF; decreased levels associated with increased mortality (14)
nts with acute RVF; increased levels (1.5 mg/dl vs. 1.25 mg/dl) suggest
nts with acute RVF; increased levels (4 mg/dl vs. 1.2 mg/dl) associated with
estion and/or hypoperfusion due to compromised LV function and forward failure
ed
g growth factor-beta–related myocardial cytokine
erm mortality in acute PE; increased value of established prognostic markers (19)
ents; increased levels associated with increase in markers of RV dysfunction (20)
nosticators in PAH (22); more accurate reflection of RV function than PAP
Hg, cardiac index 2 l/min/m2 indication for transplantation referral in PAH (22)
ed afterload is due to PAH, secondary PH, or hyperdynamic states (23)
m5: contraindication for atrial septal defect closure (24), balloon atrial
(22), pulmonary endarterectomy in CTEPH (22)
placement and transplantation-free survival in dilated cardiomyopathy (25,26)
allow for further prognostication in acute RVF, but further studies needed
and pulmonary artery elastance, flow, pulsatile pressure, and wave reflection (27)
ethod of RV afterload assessment than PVR alone (27)
ble markers of RV dysfunction (3)
ependence (3)
rgitant jet and RAP; cannot be obtained if no regurgitant jet identified
50% of measurements in PAH patients (32)
d–dependent than traditional echocardiographic markers (29–31)
f TAPSE in PAH patients; significantly decreased survival if TAPSE 1.8 cm (29)
of the listed PAC- and echocardiography-derived parameters, as well as additional advanced
ventricular; LVAD  left ventricular assist device; NT-proBNP  N-terminal pro–B-type natriuretic
ry pressure; PE pulmonary embolism; PH pulmonary hypertension; PVR pulmonary vascular
lar ejection fraction; TAPSE  tricuspid annular plane systolic excursion.ilure, and
cute
ion, ren
acute
14)
ifies R
tients
RVF an
patie
patie
14)
patie
14)
c cong
tablish
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H pati
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5 mm
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r LVAD
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Treatment of Acute Right Heart Failure October 26, 2010:1435–46fterload and increased RV contractility with levosimendan
uperior to those of dobutamine (65,66). However, use can
e limited by hypotension and arrhythmias (especially with
olus dosing) (67), and further studies in acute RVF are
eeded before its use can be recommended. Levosimendan
s currently approved for use in Europe, but not in the U.S.
trategies that decrease RV afterload by attenuating
ytokine production, endothelial dysfunction, HPV, and
icrothrombi and that may directly improve RVEF. Be-
ause the RV poorly tolerates afterload increases and because
H is a common cause of RVF, pulmonary vasodilators
epresent cornerstones of RVF treatment. All systemically
dministered pulmonary vasodilators can cause hypotension
nd need to be initiated cautiously.
iNO mediates pulmonary vasodilation by increasing cyclic
uanosine monophosphate. Rapid inactivation by hemoglobin
n the pulmonary capillaries prevents systemic vasodilation.
ffects are limited to ventilated areas of the lung, therefore
ttenuating HPV, decreasing PAP and PVR, and improving
xygenation without increasing intrapulmonary shunt fraction
Figure 2 Computed Tomography Imaging of RVF
(A to C) A 55-year-old male patient with idiopathic pulmonary arterial hypertension
drome from aspiration pneumonia. Computed tomography shows dilated pulmonar
of contrast into the inferior vena cava (C). (D) A 56-year-old man with fibrocystic s
from community-acquired pneumonia. Retrograde flow of contrast into the inferior
and high mortality.unlike systemically administered pulmonary vasodilators, phich may aggravate hypoxemia in patients with lung disease)
68,69). In addition, iNO decreases inflammatory cytokine
roduction (12,70,71). In 26 ICU patients with acute RVF, 14
atients experienced significant increases in CO and oxygen-
tion as well as decreases in PVR with iNO (35 ppm) (72).
NO use for PH and/or RVF in patients undergoing ortho-
opic heart or lung transplantation was associated with lower
ortality compared with its use in cardiac surgery or medical
atients with hypoxemia (73). Improvements in PVR and RV
ysfunction were confirmed in another study of heart trans-
lant recipients (74) and in patients with PH after mitral valve
eplacement (75). Use of iNO is limited by potential methe-
oglobinemia, production of reactive nitrogen species, and
ebound PH after rapid discontinuation (12,70,76). iNO may
e of particular benefit when combined with inodilators (do-
utamine or milrinone) (77).
Prostacyclins activate cyclic adenosine monophosphate,
esulting in pulmonary and systemic vasodilation and inhi-
ition of platelet aggregation. Although improving end
oints in pulmonary arterial hypertension (PAH) (78),
nting with right ventricular failure (RVF) due to acute respiratory distress syn-
ies (A), massive right atrial and right ventricular dilation (B), and retrograde flow
presenting with RVF due to acute hypercarbic and hypoxic respiratory failure
ava and hepatic veins is demonstrated. These findings suggest advanced RVFprese
y arter
arcoid
vena crospective data on critically ill patients with acute RVF are
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October 26, 2010:1435–46 Treatment of Acute Right Heart Failureparse. The short half-life (3 to 6 min) and its potent effects
ake epoprostenol the preferred prostacyclin in the ICU.
nitiated at 1 to 2 ng/kg/min, the drug is increased by 0.5 to
ng/kg/min every 15 to 30 min. A more cautious approach
s often warranted in critically ill patients with significant
omorbidities, hypoxemia, and/or labile hemodynamics.
poprostenol decreases PAP and PVR and increases CO,
ut its use is limited by dose-dependent side effects (e.g.,
ypotension, gastrointestinal symptoms, headaches) (79). It
hould be avoided in respiratory failure, shock, and LV
ysfunction. Similar to iNO, abrupt discontinuation may
ead to rebound PH and even death (79,80). Nebulized or
nhaled prostacyclins forgo systemic side effects, represent-
ng an attractive alternative to iNO. No special equipment is
equired for administration or toxicity monitoring. In heart
ransplant and lung transplant recipients with PH, refrac-
ory hypoxemia, and RV dysfunction, inhaled prostacyclin
ecreased PAP and CVP and improved cardiac index and
ixed venous oxygen saturation similar to iNO (81). In-
aled iloprost for RVF is supported by experimental (82)
nd clinical data. Iloprost improves PH and RV function in
atients undergoing mitral valve surgery, cardiopulmonary
ypass, or heart transplantation (83–85) and may be more
otent than iNO (86). Treprostinil decreases PAP and PVR
87), but its use in the ICU is limited by a longer half-life than
hat of epoprostenol. In unstable patients, intravenous or
nhalational administration is preferred over the subcutaneous
oute because the latter may be limited by unpredictable
bsorption. Inhaled treprostinil (15 or 30 g) additively de-
reased PVR and PAP and increased CO when added to
Figure 3 Categorization of Therapeutic Interventions Aimed at
Interventions marked with an asterisk directly or indirectly decrease right ventriculildenafil in a recent open-label trial in PH patients (88). (Endothelin receptor antagonists block endothelin-A
nd -B receptors in vascular smooth muscle and endo-
helial cells, attenuating endothelin’s vasoconstrictive,
roliferative, and proinflammatory effects (78). Although
ncreasing CO and decreasing PAP in PH patients, endo-
helin receptor antagonist use in the ICU is limited by
elatively long half-lives (5 h for bosentan) and potential
epatotoxicity (78,89), the latter occurring less frequently
ith selective endothelin-A receptor antagonists (90).
PDE-5 inhibitors block degradation of cyclic guanosine
onophosphate. They decrease PAP and increase CO in
oth acute and chronic PH and may be particularly bene-
cial for HPV (58,70,91,92). In isolated PA rings, silde-
afil, vardenafil, and tadalafil caused dose-dependent PA
elaxation and inhibited phenylephrine-induced PA con-
raction, but only tadalafil inhibited HPV and decreased
ypoxia-induced up-regulation of proinflammatory cyto-
ines (93). Few studies investigated PDE-5 inhibitors in
CU patients. In 8 patients undergoing mitral valve repair or
V assist device (LVAD) placement, sildenafil decreased
AP and PVR and facilitated weaning of inhaled and
ntravenous pulmonary vasodilators while only minimally
ecreasing systemic blood pressure (94). Sildenafil and
aprinast may act synergistically with iNO (92,95,96) or
loprost (97) and decrease rebound PH after iNO with-
rawal (98). In LVAD patients, sildenafil facilitated wean-
ng from iNO and inotropes and provided additional de-
reases in PAP (99). Sildenafil or its analogues decrease
VR, maintain systemic vascular resistance, and improve
yocardial perfusion after coronary artery bypass grafting
ving RV Function in the Intensive Care Unit
afterload. LV  left ventricular.Impro
ar (RV)100,101). Sildenafil also has unique lusitropic and/or ino-
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Treatment of Acute Right Heart Failure October 26, 2010:1435–46ropic effects in the hypertrophied RV (102), the latter being
xerted through PDE-3 inhibition (milrinone-like effect)
59). Furthermore, sildenafil decreases RV mass in PAH
atients (102,103). The drug also improves pulmonary
emodynamics and exercise capacity in patients with sys-
olic LV dysfunction (104). Hemodynamic effects of silde-
afil occur after 15 to 30 min, with peak effects after 30 to
0 min, and a half-life of 4 h. An association between
ildenafil and severe thrombocytopenia was recently re-
orted in a patient with advanced PH (105).
urgical and interventional therapies. These are indi-
ated for patients with potentially reversible RVF unrespon-
ive to or intolerant of medical therapy or for those with
isease progression despite maximal medical therapy. Sur-
ical or percutaneous correction is also used in RVF due to
alvular or congenital heart disease. Pre-operative optimi-
ation of filling pressures is crucial, and periprocedural
notropic support may be necessary. All interventions should
e performed before irreversible end-organ injury develops.
Figure 4 Treatment of Acute Right Ventricular Failure in the In
Numbers in parentheses refer to the treatment categories outlined in Figure 3. In
administration, nutritional support, and prophylactic measures should be applied.
 chronic thromboembolic pulmonary hypertension; ECMO  extracorporeal memb
ventricle; LVAD/RVAD  left/right ventricular assist device; NO  nitric oxide; PCI
embolism; PEEP  positive end-expiratory pressure; Pplat  plateau pressure; PBWurthermore, surgical or mechanical support is unlikely to penefit those with advanced RV dysfunction and/or mas-
ively elevated PVR. For example, pulmonary endarterec-
omy for chronic thromboembolic PH is not recommended
or patients with a pre-operative PVR 1,000 to 1,200
ynes·s·cm5 (22). Balloon atrial septostomy (BAS) is
ontraindicated in severe RVF and should not be offered to
atients with RAP 20 mm Hg, significant hypoxemia
90% on room air), and/or PVR index 4,400
ynes·s·cm5/m2 (12,22,106–109). Caution is indicated
hen repair of an atrial septal defect is planned in the
etting of RV dysfunction (24). PVR 1,200 dynes·s·cm5
as traditionally been accepted as a contraindication for
urgical closure. However, pre-operative pulmonary vasodi-
ator therapy may sufficiently improve hemodynamics to
llow for surgical correction (110).
In RVF due to chronic thromboembolic PH, pulmonary
hrombendarterectomy improves New York Heart Associ-
tion functional class, exercise tolerance, and survival
22,111). The best outcomes are achieved in patients with
ve Care Unit
n to the strategies depicted in the figure, general measures such as oxygen
ed from Haddad et al. (2). CHD/VHD  congenital/valvular heart disease; CTEPH
xygenation; ET-1  endothelin-1; IABP  intra-aortic balloon pump; LV  left
cutaneous coronary intervention; PDE5  phosphodiesterase 5; PE  pulmonary
edicted body weight; RRT  renal replacement therapy; VT  tidal volume.tensi
additio
Modifi
rane o
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e decreased to 500 dynes·s·cm5 (111). Surgical embo-
ectomy is used for acute massive pulmonary embolism when
hrombolysis fails or is contraindicated (112). Percutaneous
echanical approaches with or without intrapulmonary
hrombolytics can be used in this setting, but comparisons
f this approach with medical or surgical thrombolysis are
parse (112).
BAS represents a surgical right-to-left-shunt used to
unload” the RV. The associated decrease in oxygenation is
utweighed by increased oxygen delivery and mediated by
ncreased CO (107,113). BAS is used as a bridge to lung
ransplantation or as a palliative measure in refractory PH,
ut is contraindicated with concomitant LV failure (22).
pontaneous decreases in orifice size necessitating repeat
AS are not uncommon (113).
Mechanical circulatory support is usually used as a bridge
o heart, lung, or heart-lung transplantation. LVADs can be
sed to treat RVF due to LV failure. LVADs lower
re-heart transplantation PAP, which may improve long-
erm post-transplantation survival (114,115). However, be-
ause LVADs may potentially worsen pre-existing or even
esult in new-onset RVF (due to changes in RV geometry
nd flow/pressure dynamics after LV unloading), their use
eeds to be evaluated on a case-by-case basis (4,116,117).
ecent data indicate improved outcomes with continuous-
ow LVADs used in a subgroup of patients with concom-
tant RVF (118). Biventricular VADs may be used if
oncomitant RV dysfunction is present. Right VADs may
e indicated for isolated RVF. As with many surgical
rocedures, timing is of crucial importance, and VADs
hould be placed in patients with cardiogenic shock or
rogressive hemodynamic deterioration despite inotropic
herapy before irreversible end-organ failure develops (119).
owever, isolated right VADs may be insufficient or even
eleterious in cases of increased afterload, and extracorpo-
eal membrane oxygenation may be more effective in un-
oading the RV (120). Extracorporeal membrane oxygen-
tion may be considered for patients with potentially
eversible RVF due to severe hypoxemic respiratory failure
nd/or PH in whom conventional support is failing (121),
ut randomized, controlled trials are needed.
Heart, lung, or combined heart-lung transplantation is
he last resort for end-stage RVF. In patients with PAH,
VF (RAP 15 mm Hg and/or cardiac index 2.0
/min/m2) indicates poor prognosis and warrants transplan-
ation referral (22). However, due to the resilient nature of
he RV, even patients with severe RVF due to PAH can be
onsidered for isolated lung transplantation with successful
utcomes (65% to 75% 1-year-survival rate) (2,122).
onclusions and Future Directions
he RV, although commonly affected in multiple condi-
ions treated in the ICU, remains understudied and much
ess well understood than the left ventricle. Investigations ofhe treatment of isolated RVF are rare and limited to
onrandomized observations. In addition to specific thera-
ies directed against the underlying cause of RVF, support-
ve measures and judicious volume management, and the use
f selective pulmonary vasodilators in conjunction with
notropes seem most promising. The combination of iNO
ith dobutamine is best supported by current evidence, with
volving data supporting the use of inhaled prostacyclins.
DE-5 inhibitors seem to have selective actions on the RV.
echanical or surgical interventions are used as primary
reatment for distinct conditions or as rescue therapy.
Future directions should include therapies specifically
argeting the diseased RV. Examples include metabolic
odulators aimed at reversing mitochondrial dysfunction
123). Stem cells are being investigated in ischemic and
AH-related RVF (4,124–126). Tyrosine kinase inhibitors
how promise in severe PAH with RVF (127). Future
esearch should consider sex-based differences in RV func-
ion. Multiple studies demonstrate female protection in
cute and chronic forms of left ventricular injury (128,129).
ecent data indicate a similar pattern with regard to right
entricular function (130). This is of interest as healthy,
ardiovascular disease–free women have a higher RVEF
han their male counterparts (131). A better understanding
f the molecular mechanisms protecting the female RV in
ealth and disease may therefore allow future therapeutic
nterventions that ultimately benefit patients from either
ex.
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